Skip to main content

"We've detected that you're visiting from {0}. Would you like to switch languages for tailored content?"

->

3M Prevena Therapy for cardiothoracic surgery

Advancing the standard of care in cardiothoracic surgery

Cardiothoracic surgery patient care extends beyond the operating room (OR). While confidence in the OR is essential, postoperative concerns like infections, swelling and tissue integration can impact recovery. 3M™ Prevena™ Therapy provides you with a proactive strategy for incision care, elevating the standard of postoperative treatment and optimising the healing environment to enhance your patients' recovery experience.

Contact a representative
Sternum incision with 3M™ Prevena™ Peel and Place System Kit applied. MedPeople_OR_11045
Impact of Prevena Therapy Proactive Risk Management Explore More Contact us
On this page...
Impact of Prevena Therapy
Proactive Risk Management
Explore More
Contact us

Enhanced cardiothoracic surgery outcomes with Prevena Therapy

A peer-reviewed meta-analysis of 6 studies for cardiac surgical procedures demonstrated 3M™ Prevena™ Therapy helped significantly reduce the risk of surgical site infections (SSIs) compared to standard-of-care dressings.¹

Icon illustration 49.3%
Reduction in SSIs1,*

7 studies; p<0.001† 

Icon illustration 61% with down arrow
Reduction in risk of SSIs in high risk patients1,* 

2 studies; p=0.004† 

*Relative risk reduction.

†Calculation(s) are derived based on the relative patient group incidence rate reporting in this study. Statistically significant (p<0.05).

The effectiveness of Prevena Therapy in reducing the incidence of SSIs and seroma in all surgical procedures and populations has not been demonstrated. See full indications for use and limitations at hcbgregulatory.3M.com.

Explore more

Product information

Explore detailed resources including brochures, coding sheets and other informational resources offering comprehensive insights into Prevena Therapy for cardiothoracic surgery.

Contact a Solventum representative

We're here to help! Our team of representatives can provide you with information and resources to help you. Submit the form below to speak with a Solventum representative to learn more about your options.

Contact a representative

 

Looking for customer support? Visit the customer support page.

 

NOTE:


Specific indications, limitations, contraindications, warnings, precautions and safety information exist for these products and therapies. Please consult a clinician and product instructions for use prior to application. Rx only.

Prevena Dressing used with Prevena Therapy Units: PREVENA™ 125 and PREVENA PLUS™ 125 Therapy Units manage the environment of closed surgical incisions and remove fluid away from the surgical incision via the application of -125mmHg continuous negative pressure. When used with legally marketed compatible PREVENA™ dressings for up to seven days, PREVENA™ 125 and PREVENA PLUS™ 125 Therapy Units are intended to aid in reducing the incidence of seroma; and in patients at high risk for post-operative infections, aid in reducing the incidence of superficial surgical site infection in Class I and Class II wounds.

Limitations:

  • The device is not intended to treat surgical site infection or seroma.
  • Safety and effectiveness in pediatric population (<22 years old) have not been evaluated.
  • Safety and effectiveness in Class III (Contaminated) and Class IV (Dirty/Infected) wounds have not been demonstrated. Furthermore, Class IV surgical wounds are not expected to be closed primarily, and the subject device should only be used on closed surgical incisions.
  • The device has not been demonstrated to reduce deep incisional and organ space surgical site infections.
  • The device has not been demonstrated to be effective in reducing the incidence of surgical site infection and seroma in all surgical procedures and patient populations; therefore, the device may not be recommended for routine use to reduce the incidence of surgical site infection and seroma.

References:

  1. Loubani M, Cooper M, Silverman R, Bongards C, Griffin L. Surgical site infection outcomes of two different closed incision negative pressure therapy systems in cardiac surgery: Systematic review and meta-analysis. Int Wound J. 2024;21(1):e14599. doi:10.1111/iwj.14599
  2. Berríos-Torres, S. I., Umscheid, C. A., Bratzler, D. W., Leas, B., Stone, E. C., Kelz, R. R., Reinke, C. E., Morgan, S., Solomkin, J. S., Mazuski, J. E., Dellinger, E. P., Itani, K. M., Berbari, E. F., Segreti, J., Parvizi, J., Blanchard, J., Allen, G., Kluytmans, J. A., Donlan, R., & Schecter, W. P. (2017). Centers for Disease Control and Prevention guideline for the prevention of surgical site infection, 2017. JAMA Surgery, 152(8), 784. https://doi.org/10.1001/jamasurg.2017.0904
  3. Ban, K. A., Minei, J. P., Laronga, C., Harbrecht, B. G., Jensen, E. H., Fry, D. E., Itani, K. M. F., Dellinger, P. E., Ko, C. Y., & Duane, T. M. (2017). American College of Surgeons and Surgical Infection Society: Surgical Site Infection Guidelines, 2016 update. Journal of the American College of Surgeons, 224(1), 59–74. https://doi.org/10.1016/j.jamcollsurg.2016.10.029

Product availability may vary by country. For specific details regarding availability in your region, please consult with a Solventum representative.

Please note that 3M Healthcare is now operating as Solventum. The products featured on this website are now sponsored only by KCI Medical Australia Pty Ltd. (Level 3, Building A, 1 Rivett Road, North Ryde, NSW 2113), a wholly owned subsidiary of Solventum.

The products featured on this website are intended for use by qualified healthcare professionals only and are not available for purchase by the general public.